Ivosidenib (IVO; AG-120) in IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Updated Results from a Phase 1 Study
Year: 2019
Type: article
Authors: Courtney D. DiNardo, James M. Foran, Justin M. Watts, Eytan M. Stein, Stéphane de Botton, Amir T. Fathi, Gabrielle T. Prince, Anthony S. Stein, Richard M. Stone, Prapti A. Patel, Martin S. Tallman, Sung Choe, Hongfang Wang, Vickie Zhang, David Dai, Bin Fan, Katherine E. Yen, Stephanie K. Kapsalis, Denice Hickman, Samuel V. Agresta, Hua Liu, Bin Wu, Eyal C. Attar, Hagop M. Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic in Florida, University of Miami, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Massachusetts General Hospital, Johns Hopkins Hospital, City Of Hope National Medical Center, Dana-Farber Cancer Institute, The University of Texas Southwestern Medical Center, Agios Pharmaceuticals (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2971096769